4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) CEO David Kirn sold 12,930 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $23.10, for a total transaction of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
4D Molecular Therapeutics Price Performance
Shares of NASDAQ FDMT opened at $20.93 on Friday. The business has a 50-day moving average of $24.51 and a 200-day moving average of $24.61. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -8.58 and a beta of 2.89. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $9.44 and a fifty-two week high of $36.25.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.07. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. 4D Molecular Therapeutics had a negative return on equity of 26.75% and a negative net margin of 436.30%. On average, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
FDMT has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $40.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday. Barclays started coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating for the company. Jefferies Financial Group raised their price target on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, June 7th. Finally, BMO Capital Markets reduced their price objective on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, April 1st. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $45.63.
Check Out Our Latest Stock Analysis on FDMT
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More
- Five stocks we like better than 4D Molecular Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- What is a Death Cross in Stocks?
- Progress Software Stock Back in the Green After Beating Forecasts
- 10 Best Airline Stocks to Buy
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.